Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

Registrati

Quotazioni in diretta

ALNY Alnylam Pharmaceuticals Inc

245,44

6,57 (2,75%)

21 Dic 2024 - Chiuso

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/27/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

05/10/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Kevin Fitzgerald

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Alnylam Pharmaceuticals (NASDAQ:ALNY)
Storico
Da Nov 2024 a Dic 2024

Clicca qui per i Grafici di Alnylam Pharmaceuticals

Grafico Azioni Alnylam Pharmaceuticals (NASDAQ:ALNY)
Storico
Da Dic 2023 a Dic 2024

Clicca qui per i Grafici di Alnylam Pharmaceuticals

Notizie Alnylam Pharmaceuticals Inc - ALNY

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 13 Dicembre 2024 (1 settimana fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Giovedì 12 Dicembre 2024 (1 settimana fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 27 Novembre 2024 (4 settimane fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 27 Novembre 2024 (4 settimane fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 27 Novembre 2024 (4 settimane fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 27 Novembre 2024 (4 settimane fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 27 Novembre 2024 (4 settimane fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mercoledì 27 Novembre 2024 (4 settimane fa) • Edgar (US Regulatory)

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
Mercoledì 27 Novembre 2024 (4 settimane fa) • Business Wire

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Lunedì 25 Novembre 2024 (4 settimane fa) • Business Wire

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
Domenica 17 Novembre 2024 (1 mese fa) • Business Wire

Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Lunedì 4 Novembre 2024 (2 mesi fa) • Business Wire

Più Alnylam Pharmaceuticals Inc Articoli Notizie

Intesa Sanpaolo

ST Microelectronics

Banca Monte Dei Paschi D...

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea